(Q57312494)

1

0 references

E. Andrejev

2

0 references

I. Zaderey

3

0 references

U. Rudenko

4

0 references

R. Ferrari

Cardiovascular Drugs and Therapy

6

0 references

publication date

10 August 2011

0 references

published in

0 references

volume

25

0 references

issue

6

0 references

page(s)

531-537

0 references

cites work

Resting heart rate in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

Funny channels in the control of cardiac rhythm and mode of action of selective blockers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

Chronic heart failure, chronotropic incompetence, and the effects of beta blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3

Transesophageal Echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6327-3